Targeting EZH2 in cancer

Recent genomic research has led to a growing knowledge of the function of chromatin regulators in the introduction of cancer. EZH2, a histone methyl transferase subunit of the Polycomb repressor complex, is recurrently mutated in a number of types of cancer and it is highly expressed in several others. Particularly, both gain-of-function and loss-of-function mutations exist in cancers but they are connected with distinct cancer types. Ideas evaluate the spectrum of EZH2-connected mutations, discuss the mechanisms underlying EZH2 function, and synthesize a unifying perspective the promotion of cancer comes from disruption from the role of EZH2 like a master regulator of transcription. We further discuss EZH2 inhibitors which are now showing early indications of promise in numerous studies as well as additional ways of EPZ005687 combat roles of EZH2 in cancer.